Video

Immune checkpoint inhibitors show setting specific benefit in ovarian cancer meta analysis of 17 randomised trials

Immune checkpoint inhibitors show setting specific benefit in ovarian cancer meta analysis of 17 randomised trials

19 July 2026
P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

17 July 2026
Therapeutic Mammoplasty: An advanced oncoplastic breast surgery technique

Therapeutic Mammoplasty: An advanced oncoplastic breast surgery technique

16 July 2026
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

13 July 2026
Zolbetuximab plus chemotherapy in CLDN18.2-positive metastatic pancreatic cancer does not improve overall survival

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

6 July 2026
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

6 July 2026
Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

3 July 2026
Defining breast cancer quality care around the globe

Defining breast cancer quality care around the globe

1 July 2026
Global Oncology innovations - B.J.  Kennedy Award for Geriatric Oncology

Global oncology innovations: B.J. Kennedy award for geriatric oncology

30 June 2026
Global Disparities in Cancer Care for Conflict-Affected Populations: Africa's Neglected Crisis

Global disparities in cancer care for conflict-affected populations: Africa's neglected crisis

30 June 2026
Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

26 June 2026
The evolving treatment landscape in  immune thrombocytopenia

The evolving treatment landscape in immune thrombocytopenia

25 June 2026
Back to Top